Publication: Cross-clade immunogenicity and antigen-sparing with an AS03<inf>A</inf>-adjuvanted prepandemic influenza vaccine in a Thai population
Submitted Date
Received Date
Accepted Date
Issued Date
2011-08-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
01252208
eISSN
DOI
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-79961186873
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.94, No.8 (2011), 916-926
Citation
Prasert Thongcharoen, Prasert Auewarakul, Yanee Hutagalung, Gary Ong, Paul Gillard, Mamadou Drame, Hans L. Bock (2011). Cross-clade immunogenicity and antigen-sparing with an AS03<inf>A</inf>-adjuvanted prepandemic influenza vaccine in a Thai population. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/12405.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cross-clade immunogenicity and antigen-sparing with an AS03<inf>A</inf>-adjuvanted prepandemic influenza vaccine in a Thai population
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
Objective: The present study (NCT00449670) in Asian subjects (18-60 years) evaluated the manufacturing consistency of four formulations of 3.75mg AS03 A -adjuvanted H5N1 influenza vaccine, in terms of post-immunization Hemagglutination Inhibition (HI) titers against the A/Vietnam/1194/2004 and A/Indonesia/05/2005 strains. The immunogenicity and safety of the vaccine in the Thai population are reported herein. Material and Method: Subjects were randomized (2:2:2:2:1:1) between four vaccine groups and two control groups to receive two doses of either the AS03 A -adjuvanted or non-adjuvanted H5N1 vaccine formulations, 21 days apart. Sera were assayed for HI antibody titers against the two strains. Results: After the second dose of AS03 A -adjuvanted vaccine, 94.2% subjects in the H5N1-AS03 A groups seroconverted and 94.9% subjects were seroprotected against the A/Vietnam/1194/2004 strain. Cross-clade immune response against the A/Indonesia/05/2005 strain was observed. All vaccine formulations had an acceptable safety profile. Conclusion: This antigen-sparing AS03 A -adjuvanted influenza vaccine could be a suitable candidate for combating and mitigating future influenza pandemics.